E.1 Surgical Valve Replacement

E.1.1 DOAC versus VKA

Figure 2: All-cause mortality at ≤12 months for DOAC versus VKA in biological surgical valve replacement




Figure 3: Major bleeding at ≤12 months for DOAC versus VKA in biological surgical valve replacement




Figure 4: Arterial thromboembolic events at ≤12 months for DOAC versus VKA in biological surgical valve replacement




Figure 5: Hospital re-admission at 12 months for DOAC versus VKA in biological surgical valve replacement





Figure 6: Thrombus on imaging at ≤12 months for DOAC versus VKA in biological surgical valve replacement



E.1.2 VKA versus SAPT

Figure 7: All-cause mortality at ≤12 months for VKA versus SAPT in biological surgical valve replacement

	VKA		SAPT			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Colli 2007 (WoA Epic)	2	34	2	35	24.4%	1.03 [0.15, 6.90]	
Rafiq 2017	8	167	6	161	75.6%	1.29 [0.46, 3.62]	
Total (95% CI)		201		196	100.0%	1.22 [0.49, 3.04]	
Total events	10		8				
Heterogeneity: Chi² = 0.1	04, df = 1	(P = 0.5)	01 02 05 1 2 5 10				
Test for overall effect: Z = 0.43 (P = 0.66)							Favours VKA Favours SAPT

Figure 8: Major bleeding at ≤12 months for VKA versus SAPT in biological surgical valve replacement

	VKA		SAPT			Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
Colli 2007 (WoA Epic)	3	34	1	35	24.4%	3.09 [0.34, 28.25]		-	
Rafiq 2017	9	167	3	161	75.6%	2.89 [0.80, 10.49]		+-	_
Total (95% CI)		201		196	100.0%	2.94 [0.97, 8.95]			
Total events	12		4						
Heterogeneity: $Chi^2 = 0.00$, $df = 1$ (P = 0.96); $I^2 = 0\%$							0.01	01 1	10 100
Test for overall effect: Z = 1.90 (P = 0.06)							0.01	Favours VKA Favours S	

Figure 9: Arterial thromboembolic events at ≤12 months for VKA versus SAPT in biological surgical valve replacement

		J								
	VKA		SAPT			Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI		
Colli 2007 (WoA Epic)	1	34	2	35	15.0%	0.51 [0.05, 5.42]	+	<u> </u>		
Rafiq 2017	10	167	11	161	85.0%	0.88 [0.38, 2.01]				
Total (95% CI)		201		196	100.0%	0.82 [0.38, 1.79]				
Total events	11		13							
Heterogeneity: Chi² = 0.17, df = 1 (P = 0.68); l² = 0%							0.1	0.2 0.5 1 2 5 10		
Test for overall effect: Z = 0.49 (P = 0.62)							0.1	Favours VKA Favours SAPT		

Figure 10: Hospital re-admission at 12 months for VKA versus SAPT in biological surgical valve replacement





Figure 11: Thrombus on imaging at ≤12 months for VKA versus SAPT in biological surgical valve replacement



E.1.3 VKA and SAPT versus VKA alone in surgical valve replacement

Figure 12: Major systemic embolism or death from vascular causes at ≤12 months for VKA and SAPT versus VKA alone in biological surgical valve replacement

